Stay updated on Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label changes from v3.8.0 to v3.8.1, while the study record content remains unchanged.
    Difference
    0.1%
    Check dated 2026-11-22T02:40:12.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The record displays details for the pembrolizumab study, including its completed status, eligibility criteria, treatment plan, outcome measures, study locations, and results-related information.
    Difference
    45%
    Check dated 2026-11-08T05:24:29.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-01T02:30:51.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    A site-wide notice announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to transition updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T02:33:45.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The site footer now displays revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-18T02:21:17.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T03:24:02.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.